GSK3 inhibitors: Development and therapeutic potential

Philip Cohen, Michel Goedert

    Research output: Contribution to journalReview article

    599 Citations (Scopus)

    Abstract

    Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.

    Original languageEnglish
    Pages (from-to)479-487
    Number of pages9
    JournalNature Reviews Drug Discovery
    Volume3
    Issue number6
    DOIs
    Publication statusPublished - 1 Jan 2004

    Fingerprint Dive into the research topics of 'GSK3 inhibitors: Development and therapeutic potential'. Together they form a unique fingerprint.

  • Cite this